CeBIL, Faculty of Law, University of Copenhagen, invites applications for two fully funded three-year PhD scholarships. We are looking for candidates with innovative and original ideas.
Successful candidates can start on 1 May 2019.
The Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) explores the legal challenges and the rapid developments in the biotechnological area. CeBIL brings together scholars from some of the world’s leading research institutions in interdisciplinary collaboration as well as stakeholders from industry, government and civil society. Alongside other projects, CeBIL hosts the Collaborative Research Programme for Biomedical Innovation Law (CeBIL Programme). This 5-year research programme (2018-22) is supported by a grant of DKK 35 million from the Novo Nordisk Foundation and involves partners from Cambridge, Harvard Law School, Harvard Medical School, Michigan, and the UCPH IFRO.
The CeBIL Programme focuses on innovation inefficiencies on the life science frontiers through five concrete interrelated studies. The common aim of the five studies is to optimise legal concepts into enabling tools that will help bring novel technologies, research, and biomedicine together for radical innovation – thereby providing much-needed contribution to bridging bio-pharmaceutical innovation gaps, enhancing translational medicine, and promoting technology transfer. An overarching study on Policy & Synergy will ensure continuous knowledge exchange and synergy across the five concrete studies:
Study 1: Antibiotics
Study 2: Orphan Drugs
Study 3: Precision Medicine
Study 4: New Uses
Study 5: Drug Manufacturing & Biologics
Study 6: Policy & Synergy
The objective of the CeBIL Programme is to demonstrate how legal science methods that take careful account of interdisciplinary insights and “real world” perspectives can generate new knowledge about key factors driving pharmaceutical innovation. In addition, such methods will be utilised to examine how innovation incentives, other than patents, can be applied, combined, optimised and conceptualised in order to either substitute or complement patent protection in new areas of crucial medical applications.
The two PhD researchers will be included in the two studies listed below: Studies 1 and 6. The CeBIL management, however, reserves the right to recruit candidates for one of the other four studies instead, should their academic profile and research plan provide an even better fit for the CeBIL Programme as a whole.
Against the background of increasing antibiotic resistance and inadequate market incentives, Study 1 will evaluate the legal implications of a number of “push” and “pull” options to tackle these challenges. This includes ﬁnancial incentives, such as speciﬁc IP protection and market exclusivities, health impact funds, crowd-funding, pre-competitive collaborations, PPPs between academia and the industry, and other innovative alternatives, such as “integrated” strategies based on prizes administered by reimbursement systems that require compliance with conservation targets. Among the key questions that will have to be addressed are the following ones: (1) To what extent is there a need to curtail and combine particular push and pull incentives to different classes of antibiotic resistance? (2) What are the pros and cons of purely market-based incentives in comparison to delinkage models in the ﬁght against antibiotic resistance? (3) To what extent would so-called complementary approaches, more public-private collaboration, or “integrated strategies” be helpful in European settings compared to the US and what legal changes would be required to implement such approaches? (4) Do we need to reconsider the already available incentives and deﬁnitions in the current “antibiotics” legislation in light of new scientiﬁc insights and bio-medical applications? (5) What potential do new forms of therapies based on gene-editing, such as CRISPR-Cas 9 and gene drive, and phage technologies have in the ﬁght against AMR and what are the legal and ethical dimensions?
As part of Study 6 to develop a framework that integrates law, ethical considerations, economics, science, business and policy to support biomedical innovation, the legal sub-study “Towards an Improved and Sustainable Legal Framework for Biomedical Innovation” will address the following key research questions: (1) What common legal principles can be derived from each of the five concrete studies and how can they be synthesised and organized to form a conceptual framework with a sound underlying legal theory that can be translated into recommendations for new legislation? (2) How can those legal ﬁndings be applied to inform and shape both general innovation policy debates and more speciﬁc debates, such as on the role that alternative R&D incentives could play in the raging controversy over the patentability of biomedical products and methods? (3) What is the proper role for ethical considerations, e.g. on patient rights and access to medicines?
PhD students at CeBIL are enrolled in the Faculty of Law’s general doctoral training programme, which provides PhD students with a general set of skills for developing their research and career. This programme involves coursework, international networking, a research visit at a relevant research institution abroad, as well as teaching tasks. Details and requirements can be found on the Faculty's website. Some of the requirements can, however, be fulfilled by participating in CeBIL’s own research training activities.
Click ’Apply now’ below to be taken to the online application form.
We advise you to have the following documents ready before you begin your online application:
Submit your application electronically in English.
Following the application deadline, the Dean will pre-select PhD applications that will proceed to the assessment stage upon the recommendation of the Selection Committee. Applicants are pre-selected for further assessment in line with the Faculty’s recruitment needs as described in this job advertisement. This is carried out based on the overall assessment of the applicant’s educational qualifications, the quality of the submitted research proposal and its relevance to the Faculty’s research agenda, and other relevant qualifications (e.g. relevant professional experience, any previous academic publications etc.). All applicants are then notified by the HR Centre as to whether their application has proceeded to the assessment stage. The assessment is carried out by an expert assessment committee. Selected applicants will be notified of the composition of the assessment committee. When the committee has completed its assessment, each applicant has the opportunity to comment on the assessment. A number of qualified applicants will be invited for an interview. Interviews are expected to take place in February/March 2019.
Successful candidates will be employed in accordance with the agreement between the Danish Confederation of Professional Associations and the Ministry of Finance concerning the salary of PhD students. If you are offered a PhD position, you will receive a regular monthly salary in accordance with Danish law and you will be entitled to an annual research budget. The Faculty does not provide accommodation.
The closing date for applications is 1 December 2018, 23:59 GMT +1. Applications received after the deadline will not be considered. Likewise incomplete applications (i.e. without all required documents) will be rejected.
Part of the International Alliance of Research Universities (IARU), and among Europe’s top-ranking universities, the University of Copenhagen promotes research and teaching of the highest international standard. Rich in tradition and modern in outlook, the University gives students and staff the opportunity to cultivate their talent in an ambitious and informal environment. An effective organisation – with good working conditions and a collaborative work culture – creates the ideal framework for a successful academic career.